5:40 PM
Feb 18, 2010
 |  BC Extra  |  Politics & Policy

FDA requires REMS for LABAs

FDA will require manufacturers to update the labels for long-acting beta-2 adrenergic agonists (LABAs) to treat asthma, as well as conduct additional safety studies for the drugs and develop a risk evaluation and mitigation strategy (REMS). The agency noted that clinical...

Read the full 184 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >